Singula Bio is a seed-stage biotechnology company that was spun out of the University of Oxford. The company is focused on developing novel neoantigen-based cell therapies for patients with solid tumours. Singula Bio aims to become a world leader in providing individualised cell therapies for cancer. We have developed immunological, medical, surgical and computational technologies to develop selective therapies for difficult-to-treat solid malignancies such as ovarian cancer.
Our Mission
At Singula Bio, we believe that cancer need not be fatal. Our mission is to create individualised cell therapy options for cancer patients to prevent recurrence and prolong survival.
Our story
At Singula Bio, we believe that “Cancer Need Not be Fatal”. We take a patient-centered approach to provide logical and effective therapies by using groundbreaking approaches challenging existing cancer treatment methods. Our vision is to provide individualised cell therapies to eliminate cancer to achieve long-term, high-quality and disease-free survival for patients.
Ahmed Ahmed and Enzo Cerundolo embarked on a mission to eliminate suffering from cancer. Their vision was a patient-first approach that combined with their expertise, know-how and innovative technologies to design patient-specific cancer cell therapies. that harnesses the power of the patient’s own immune system to fight cancer. They brought together their combined knowledge in cancer medicine, cancer immunology, cell and molecular biology, computational biology and surgery to establish what is now known as Singula Bio. Enda McVeigh later joined the team to help turn this vision into a reality, bringing forward his wealth of experience in live-cell therapy and his Reproductive Medicine background. Sadly, Enzo passed away in January 2020 before seeing Singula Bio come to fruition but his colleagues are determined to keep the legacy going and to realise their vision- Cancer need not be fatal.
Professor Ahmed Ahmed
Professor Vincenzo Cerundolo
